Domino Data Lab and Appsilon have announced a partnership aimed at enhancing the deployment of AI in the life sciences sector, addressing the challenges faced by organizations in moving from development to production.
The collaboration focuses on leveraging open-source AI within regulated environments, which is crucial for pharmaceutical companies. By integrating Appsilon's expertise in R and Python with Domino's AI platform, the partnership aims to streamline the transition of data science projects into validated production environments. This is particularly important as many life sciences organizations struggle with inadequate infrastructure, which can hinder the deployment of AI applications.
Joint customers will benefit from a comprehensive approach that combines Appsilon's deep industry knowledge with Domino's governance capabilities. This includes facilitating SAS-to-open-source migration and providing a compliant environment for data scientists to work efficiently. The partnership also introduces Appsilon's Axon.R, a validation tool designed to enhance compliance within the Domino platform.
This collaboration highlights the growing need for robust infrastructure in the life sciences sector, allowing organizations to harness the full potential of AI while meeting stringent regulatory requirements. As the industry evolves, the ability to integrate advanced tools seamlessly into existing workflows will be essential for accelerating drug development and improving patient outcomes.